[Skip to Content]
Access to paid content on this site is currently suspended due to excessive activity being detected from your IP address Please contact the publisher to request reinstatement.
[Skip to Content Landing]
Books, Journals, New Media
July 28, 1999


Author Affiliations

Margaret A.WinkerMD, Deputy EditorIndividualAuthorPhil B.FontanarosaMD, Interim CoeditorIndividualAuthor

JAMA. 1999;282(4):329. doi:10-1001/pubs.JAMA-ISSN-0098-7484-282-4-jbk0728

To the Editor: In 1994 we reported a cost-effectiveness analysis for solvent-detergent–treated frozen plasma (SDFP),1 in which we calculated a cost of $289,300 per quality-adjusted life year (QALY) saved. Solvent-detergent treatment involves pooling several thousand units of donated plasma, then applying a detergent to inactivate enveloped viruses such as human immunodeficiency virus (HIV), hepatitis C virus (HCV), and hepatitis B virus (HBV). This technique decreases the transmission risk for these viruses, although it theoretically can increase the transmission risk for nonenveloped viruses. Despite the poor projected cost-effectiveness of SDFP, the Food and Drug Administration has recently licensed it for use in the United States, with distribution being handled by the American Red Cross Blood Services.

First Page Preview View Large
First page PDF preview
First page PDF preview